Publications by authors named "Takehiro Fukami"

Claim this Profile
D
Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.
Yasuko Koda, Shin Sato, Hirofumi Yamamoto, Hideaki Niwa, Hisami Watanabe, Takehiro Fukami

ACS Med Chem Lett· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection.
Toshitada Takemori, Akiko Sugimoto-Ishige, Hironori Nishitsuji, Yushi Futamura, Michishige Harada, Takehiro Fukami

J Virol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ubiquinone synthesis pathway is a promising drug target for Chagas disease.
Takeshi Nara, Yukari Nakagawa, Keiko Tsuganezawa, Hitomi Yuki, Katsuhiko Sekimata, Takehiro Fukami

PLoS One· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.
Mari Hashimoto, Yoriko Saito, Ryo Nakagawa, Ikuko Ogahara, Shinsuke Takagi, Takehiro Fukami

Nat Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel tankyrase inhibitors suppress TDP-43 aggregate formation.
Kunikazu Tanji, Fumiaki Mori, Fumiyuki Shirai, Takehiro Fukami, Hiroyuki Seimiya

Biochem Biophys Res Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Fumiyuki Shirai, Anna Mizutani, Yoko Yashiroda, Takeshi Tsumura, Yuko Kano, Takehiro Fukami

J Med Chem· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of small molecule inhibitors of human COQ7.
Keiko Tsuganezawa, Katsuhiko Sekimata, Yukari Nakagawa, Rei Utata, Kana Nakamura, Takehiro Fukami

Bioorg Med Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Fumiyuki Shirai, Takeshi Tsumura, Yoko Yashiroda, Hitomi Yuki, Hideaki Niwa, Takehiro Fukami

J Med Chem· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
Anna Mizutani, Yoko Yashiroda, Yukiko Muramatsu, Haruka Yoshida, Tsubasa Chikada, Takehiro Fukami

Cancer Sci· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways.
Yoriko Saito, Yoshiki Mochizuki, Ikuko Ogahara, Takashi Watanabe, Leah Hogdal, Takehiro Fukami

Sci Transl Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
Yoriko Saito, Hitomi Yuki, Mitsuo Kuratani, Yoshinobu Hashizume, Shinsuke Takagi, Takehiro Fukami

Sci Transl Med· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.
Yuji Haga, Toshihiro Sakamoto, Takunobu Shibata, Katsumasa Nonoshita, Makoto Ishikawa, Takehiro Fukami

Bioorg Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.
Hirobumi Takahashi, Yuji Haga, Takunobu Shibata, Katsumasa Nonoshita, Toshihiro Sakamoto, Takehiro Fukami

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Takao Suzuki, Minoru Kameda, Makoto Ando, Hiroshi Miyazoe, Etsuko Sekino, Takehiro Fukami

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
Satoshi Mashiko, Ryuichi Moriya, Akane Ishihara, Akira Gomori, Hiroko Matsushita, Takehiro Fukami

Eur J Pharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists.
Hiroyuki Kishino, Minoru Moriya, Shunji Sakuraba, Toshihiro Sakamoto, Hidekazu Takahashi, Takehiro Fukami

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
Makoto Ando, Nagaaki Sato, Tsuyoshi Nagase, Keita Nagai, Shiho Ishikawa, Takehiro Fukami

Bioorg Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
Ryuichi Moriya, Satoshi Mashiko, Akane Ishihara, Toshiyuki Takahashi, Takashi Murai, Fukami Takehiro

Peptides· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists.
Minoru Moriya, Hiroyuki Kishino, Shunji Sakuraba, Toshihiro Sakamoto, Takuya Suga, Takehiro Fukami

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Minoru Moriya, Osamu Okamoto, Takehiro Fukami

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.
Toshihiro Sakamoto, Minoru Moriya, Hiroyasu Tsuge, Toshiyuki Takahashi, Yuji Haga, Takehiro Fukami

Bioorg Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists.
Takao Suzuki, Minoru Moriya, Toshihiro Sakamoto, Takuya Suga, Hiroyuki Kishino, Takehiro Fukami

Bioorg Med Chem Lett· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(-)-Ternatin inhibits adipogenesis and lipid metabolism in 3T3-L1 cells.
Masahiko Ito, Junko Ito, Hidefumi Kitazawa, Ken Shimamura, Takehiro Fukami

Peptides· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
Nagaaki Sato, Makoto Ando, Shiho Ishikawa, Makoto Jitsuoka, Keita Nagai, Takehiro Fukami

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.
Toshihiro Sakamoto, Minoru Moriya, Yuji Haga, Toshiyuki Takahashi, Takunobu Shibata, Takehiro Fukami

Bioorg Med Chem Lett· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis